Novartis announced higher sales figures for 2025, driven by strong performance across its product portfolio. Despite this growth, the company expects a decrease in core operating profit for the current year.
The pharmaceutical firm faces ongoing challenges from generic drug competition in the U.S. market, which is influencing its profit outlook. Novartis continues to focus on innovation and expanding its pipeline to sustain long-term growth.
**Why this matters**
Novartis is a key player in the global pharmaceutical industry, and its financial results provide insight into market trends, including the impact of generic drugs on established products. Understanding these dynamics helps investors and stakeholders assess the company’s future performance and strategic direction.
Source: NewsData